The PEG-enhanced version of L-asparaginase, pegaspargase (Oncaspar, Enzon Pharmaceuticals), has been approved by the FDA as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL). The biologic was approved in 1994 only for patients with ALL who were allergic to L-asparaginase.
New indication for Oncaspar given OK
The PEG-enhanced version of L-asparaginase, pegaspargase (Oncaspar, Enzon Pharmaceuticals), has been approved by the FDA as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL). The biologic was approved in 1994 only for patients with ALL who were allergic to L-asparaginase. In clinical trials, pegaspargase demonstrated a three-year event-free survival rate of approximately 80%. Due to its longer half-life, said the manufacturer, one dose of pegaspargase results in antileukemic activity similar to six to nine doses of unmodified L-asparaginase, resulting in a more convenient dosage regimen of every 14 days versus twice weekly.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Improved Understanding of Hidradenitis Suppurativa Can Enhance Patient Outcomes
July 14th 2025Researchers assessed the difference between hidradenitis suppurativa and other skin conditions regarding the initiating events, inflammatory signature, and molecular and clinical features of each disease.